Table 3.

Genotypes of the HPA-2 Polymorphism in Case Patients and Controls

CVD CHDDVT
No. of Patients (%) No. of Controls (%) No. of Patients (%) No. of Controls (%)No. of Patients (%) No. of Controls (%)
Genotype P = .0244  OR = 2.40  P = .0375 OR = 2.09  P = .6729  
 a/a 81 (77.9)  93 (89.4)  74 (73.3)  86 (85.2) 83 (87.4)  81 (85.3)  
 a/b + b/b  22 + 1 (22.1) 10 + 1 (10.6)  27 + 0 (26.7)  13 + 2 (14.9) 12 + 0 (12.6)  12 + 2 (14.7) 
CVD CHDDVT
No. of Patients (%) No. of Controls (%) No. of Patients (%) No. of Controls (%)No. of Patients (%) No. of Controls (%)
Genotype P = .0244  OR = 2.40  P = .0375 OR = 2.09  P = .6729  
 a/a 81 (77.9)  93 (89.4)  74 (73.3)  86 (85.2) 83 (87.4)  81 (85.3)  
 a/b + b/b  22 + 1 (22.1) 10 + 1 (10.6)  27 + 0 (26.7)  13 + 2 (14.9) 12 + 0 (12.6)  12 + 2 (14.7) 

χ2 test was used to compare the values of the distribution of HPA-2 genotypes among case patients and controls.

Abbreviations: CVD, cerebrovascular disease; CHD, coronary heart disease; DVT, deep venous thrombosis; OR, odds ratio.

or Create an Account

Close Modal
Close Modal